SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Dino's Bar & Grill

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Goose94 who wrote (57359)4/5/2019 9:59:58 AM
From: Goose94Read Replies (1) of 202988
 
Preveceutical Medical (PREV-Cse) retracts statements in April 4th NR

At the request of the Investment Industry Regulatory Organization of Canada, Preveceutical Medical Inc. is retracting certain statements regarding estimated annual production, valuation and harvest quantities from the Toowoomba medicinal cannabis project contained in its news release dated April 4, 2019. The presentation of this information is not consistent with requirements for the disclosure of forward-looking information.

About Preveceutical Medical Inc.

Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics, such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For further information, please contact:

PREVECEUTICAL MEDICAL INC.
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext